← back to search

John S. Welch

Washington University in St. Louis · US
Area of research
Hematology · Molecular Biology
Research interest
Research interests include Acute Myeloid Leukemia Research, Retinoids in leukemia and cellular processes, Cancer Genomics and Diagnostics, and CAR-T cell therapy research.
h-index
47
citations
23,847
works
313
NIH funding
primary concept
email

Recent publications

EVEREST-2: Initial data of the logic-gated Tmod chimeric antigen receptor T-cell (CAR T) therapy A2B694 for patients with solid tumors associated with mesothelin (MSLN) expression and with human leukocyte antigen (HLA) loss of heterozygosity (LOH).
Journal of Clinical Oncology 2025cited by 6position: middledoi
535 EVEREST-2: a phase 1/2 study of A2B694, a logic-gated Tmod CAR T therapy to treat solid tumors expressing mesothelin (MSLN) with HLA-A*02 loss of heterozygosity: initial safety and efficacy results
Regular and Young Investigator Award Abstracts 2025cited by 2position: middledoi
Detecting HLA loss of heterozygosity within a standard diagnostic sequencing workflow for prognostic and therapeutic opportunities
npj Precision Oncology 2024cited by 14position: middledoi
EVEREST-2: A seamless phase 1/2 study of A2B694, a mesothelin (MSLN) logic-gated Tmod CAR T-cell therapy, in patients with solid tumors that show MSLN expression and human leukocyte antigen (HLA)-A*02 loss of heterozygosity (LOH).
Journal of Clinical Oncology 2024cited by 7position: middledoi
A global study for acute myeloid leukemia with <i>RARG</i> rearrangement
Blood Advances 2023cited by 26position: middledoi
639 BASECAMP-1: Leveraging HLA loss of heterozygosity in solid tumors by NGS to identify patients with relapsed solid tumors for future CEA and MSLN logic-gated Tmod™ CAR T-cell therapy
Regular and Young Investigator Award Abstracts 2022cited by 0position: middledoi
<i>TP53</i> and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes
New England Journal of Medicine 2016cited by 783position: firstdoi
Genomic analysis of germ line and somatic variants in familial myelodysplasia/acute myeloid leukemia
Blood 2015cited by 237position: middledoi
Age-related mutations associated with clonal hematopoietic expansion and malignancies
Nature Medicine 2014cited by 1,877position: middledoi
Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia
Nature 2014cited by 877position: middledoi
Mutational landscape and significance across 12 major cancer types
Nature 2013cited by 4,487position: middledoi
Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing
Nature 2012cited by 2,005position: middledoi
The Origin and Evolution of Mutations in Acute Myeloid Leukemia
Cell 2012cited by 1,564position: firstdoi

Grants

Tetrafluoro(trifluoromethyl)sulfanes Chemical Reactivity and Polar Hyrdophobicity
NSF2154772$472,3692022–2027PIRePORTER
I-Corps: Novel Monomers and Chemistries for Photopolymerization of Coatings and Adhesives
NSF1640918$50,0002016–2017PIRePORTER
Control of Conformation and Reactivity in Pentafluorosulfanyl and Tetrafluorosulfanyl Substituted Aliphatic Compounds
NSF1464936$385,9802015–2021PIRePORTER
The Preparation and Utility of Pentafluorosulfanyl Substituted Aliphatic Compounds
NSF0957544$375,0002010–2014PIRePORTER
Purchase of 400 MHz NMR Spectrometer
NSF0342660$233,1502004–2007PIRePORTER
Acquisition of CCD-Based X-Ray Diffractometer
NSF0130985$180,2502002–2005PIRePORTER
New Strategies for the Enantioselective Synthesis of Fluorinated Molecules
NSF9413004$225,0001995–1998PIRePORTER
Stereo- and Enantioselective Synthesis with Fluorinated Reagents
NSF8901986$181,6741989–1993PIRePORTER
Enantioselective Reactions of Fluorinated Reagents (Chemistry)
NSF8520875$139,6891986–1989PIRePORTER
Fy 81 Science Faculty Professional Development Program
NSF8165063$27,5001981–1984PIRePORTER

Frequent collaborators

Li Ding · South China Institute of Collaborative Innovation3 papers (2013–2014)Christopher A. Miller · University of Manchester3 papers (2013–2014)J. Randolph Hecht · Comprehensive Cardiovascular3 papers (2024–2025)Richard K. Wilson · Nationwide Children's Hospital3 papers (2013–2014)David G. Maloney · Fred Hutch Cancer Center3 papers (2024–2025)Matthew J. Walter · École de management de Lyon3 papers (2013–2014) · 3 papers (2024–2025)Julian R. Molina · Roswell Park Comprehensive Cancer Center3 papers (2024–2025)Timothy J. Ley · University of Missouri–St. Louis3 papers (2013–2014)Jeffrey D. Ward · National Taiwan University2 papers (2024–2025)Michael D. McLellan · James S. McDonnell Foundation2 papers (2013–2014)William Y. Go · Amgen (United States)2 papers (2024–2024)Mingchao Xie · AstraZeneca (United States)2 papers (2013–2014)Matthew S. Block · Mayo Clinic2 papers (2024–2025) · 2 papers (2024–2025)Leslie R. Boyd · New York University2 papers (2024–2025)Maria Pia Morelli · National Heart Lung and Blood Institute2 papers (2024–2025)Marcela V. Maus · Harvard University2 papers (2024–2025)Diane M. Simeone · NYU Langone’s Laura and Isaac Perlmutter Cancer Center2 papers (2024–2024)Michael C. Wendl · Centre for Genomic Regulation2 papers (2013–2014)